Effect of Environmental Exposure and Pharmacogenomics on Drug Metabolism

被引:9
作者
Banerjee, Basu Dev [1 ,2 ]
Kumar, Ranjeet [1 ,2 ]
Thamineni, Krishna Latha [1 ,2 ]
Shah, Harendra [1 ,2 ]
Thakur, Gaurav Kumar [1 ,2 ]
Sharma, Tusha [1 ,2 ]
机构
[1] Univ Delhi, Dept Biochem, Environm Biochem & Mol Biol Lab, Univ Coll Med Sci, Delhi 110095, India
[2] Univ Delhi, GTB Hosp, Delhi 110095, India
关键词
Environmental pollutants; xenobiotics; drug metabolism; Phase I and II metabolizing genes; pharmacogenomics; pesticides; GLUTATHIONE-S-TRANSFERASE; LINDANE INDUCED TOXICITY; AGE-RELATED-CHANGES; CYP2D6; GENE; CYTOCHROME-P450; ENZYMES; MOLECULAR-MECHANISMS; TAMOXIFEN METABOLISM; CYP3A7; EXPRESSION; HUMAN LIVER; POLYMORPHISMS;
D O I
10.2174/1389200221666200110153304
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Pesticides are major xenobiotic compounds and environmental pollutants, which are able to alter drug-metabolizing enzyme as well as pharmacokinetics of drugs. Subsequent to the release of the human genome project, genetic variations (polymorphism) become an integral part of drug development due to their influence on disease susceptibility/ progression of the disease and their impact on drug absorption, distribution, metabolism of active metabolites and finally excretion of the drug. Genetic polymorphisms crucially regulate pharmacokinetics and pharmacodynamics of drugs under the influence of physiological condition, lifestyle, as well as pathological conditions collectively. Objective: To review all the evidence concerning the effect of environmental exposure on drug metabolism with reference to pharmacogenomics. Methods: Scientific data search and review of basic, epidemiological, pharmacogenomics and pharmacokinetics studies were undertaken to evaluate the influence of environmental contaminants on drug metabolism. Results: Various environmental contaminants like pesticides effectively alter drug metabolism at various levels under the influence of pharmacogenomics, which interferes with pharmacokinetics of drug metabolism. Genetic polymorphism of phase I and phase II xenobiotic-metabolizing enzymes remarkably alters disease susceptibility as well as the progression of disease under the influence of various environmental contaminants at various levels. Conclusion: Individual specific drug response may be attributed to a large variety of factors alone or in combination ranging from genetic variations (SNP, insertion, deletion, duplication etc.) to physiological setting (gender, age, body size, and ethnicity), environmental or lifestyle factors (radiation exposure, smoking, alcohol, nutrition, exposure to toxins, etc.); and pathological conditions (obesity, diabetes, liver and renal function).
引用
收藏
页码:1103 / 1113
页数:11
相关论文
共 119 条
[71]   Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution [J].
Marez, D ;
Legrand, M ;
Sabbagh, N ;
LoGuidice, JM ;
Spire, C ;
Lafitte, JJ ;
Meyer, UA ;
Broly, F .
PHARMACOGENETICS, 1997, 7 (03) :193-202
[72]   Glutathione S-transferase polymorphisms:: cancer incidence and therapy [J].
McIlwain, CC ;
Townsend, DM ;
Tew, KD .
ONCOGENE, 2006, 25 (11) :1639-1648
[73]   Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians [J].
McLellan, RA ;
Oscarson, M ;
Seidegard, J ;
Evans, DAP ;
IngelmanSundberg, M .
PHARMACOGENETICS, 1997, 7 (03) :187-191
[74]   Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer [J].
Nagar, S ;
Remmel, RP .
ONCOGENE, 2006, 25 (11) :1659-1672
[75]   CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population [J].
Niewinski, P ;
Orzechowska-Juzwenko, K ;
Hurkacz, M ;
Rzemislawska, Z ;
Jazwinska-Tarnawska, E ;
Milejski, P ;
Forkasiewicz, Z .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (08) :533-535
[76]   Pharmacogenetics of human cytosolic sulfotransferases [J].
Nowell, S ;
Falany, CN .
ONCOGENE, 2006, 25 (11) :1673-1678
[77]   INDUCTION OF DRUG-METABOLIZING-ENZYMES - MECHANISMS AND CONSEQUENCES [J].
OKEY, AB ;
ROBERTS, EA ;
HARPER, PA ;
DENISON, MS .
CLINICAL BIOCHEMISTRY, 1986, 19 (02) :132-141
[78]   Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure-Activity Relationships and Discovery Strategies To Mitigate Drug-Drug Interaction Risks [J].
Orr, Suvi T. M. ;
Ripp, Sharon L. ;
Ballard, T. Eric ;
Henderson, Jaclyn L. ;
Scott, Dennis O. ;
Obach, R. Scott ;
Sun, Hao ;
Kalgutkar, Amit S. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (11) :4896-4933
[79]   Protective effect of gallic acid against lindane induced toxicity in experimental rats [J].
Padma, V. Vijaya ;
Sowmya, P. ;
Felix, T. Arun ;
Baskaran, R. ;
Poornima, P. .
FOOD AND CHEMICAL TOXICOLOGY, 2011, 49 (04) :991-998
[80]   Amodiaquine metabolism is impaired by common polymorphisms inCYP2C8: Implications for malaria treatment in Africa [J].
Parikh, S. ;
Ouedraogo, J-B ;
Goldstein, J. A. ;
Rosenthal, P. J. ;
Kroetz, D. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (02) :197-203